New Risk • May 05
New major risk - Revenue and earnings growth Earnings have declined by 23% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 23% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change). Reported Earnings • Apr 30
Full year 2025 earnings released: EPS: CN¥0.03 (vs CN¥0.45 loss in FY 2024) Full year 2025 results: EPS: CN¥0.03 (up from CN¥0.45 loss in FY 2024). Revenue: CN¥1.13b (up 17% from FY 2024). Net income: CN¥13.4m (up CN¥239.9m from FY 2024). Profit margin: 1.2% (up from net loss in FY 2024). Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 4% per year. Annuncio • Apr 29
ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 28, 2026 ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 28, 2026, at 13:30 China Standard Time. Location: Building A, No. 2829, Jinke Road, Zhangjiang Hi-tech Park, Pudong New Area, Shanghai China New Risk • Apr 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 36% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (9.6% average weekly change). Annuncio • Mar 31
ChemPartner PharmaTech Co.,Ltd. to Report Q1, 2026 Results on Apr 29, 2026 ChemPartner PharmaTech Co.,Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026 Annuncio • Dec 31
ChemPartner PharmaTech Co.,Ltd. to Report Fiscal Year 2025 Results on Apr 29, 2026 ChemPartner PharmaTech Co.,Ltd. announced that they will report fiscal year 2025 results on Apr 29, 2026 Reported Earnings • Oct 30
Third quarter 2025 earnings released: CN¥0.036 loss per share (vs CN¥0.002 profit in 3Q 2024) Third quarter 2025 results: CN¥0.036 loss per share (down from CN¥0.002 profit in 3Q 2024). Revenue: CN¥283.1m (up 12% from 3Q 2024). Net loss: CN¥18.3m (down CN¥19.5m from profit in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Annuncio • Sep 30
ChemPartner PharmaTech Co.,Ltd. to Report Q3, 2025 Results on Oct 30, 2025 ChemPartner PharmaTech Co.,Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025 Annuncio • Jul 02
ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2025 Results on Aug 29, 2025 ChemPartner PharmaTech Co.,Ltd. announced that they will report first half, 2025 results on Aug 29, 2025 Annuncio • May 22
Jiangmen Ruilian Pharmaceutical Investment Co., Ltd. completed the acquisition of 5.35% stake in ChemPartner PharmaTech Co.,Ltd. (SZSE:300149) from Yunnan Baben Health Industry Co., Ltd. Jiangmen Ruilian Pharmaceutical Investment Co., Ltd. agreed to acquire 5.35% stake in ChemPartner PharmaTech Co.,Ltd. (SZSE:300149) from Yunnan Baben Health Industry Co., Ltd. for approximately CNY 130 million on March 31, 2025. The consideration consist of CNY 5.064 per ChemPartner PharmaTech Co.,Ltd. share.
Jiangmen Ruilian Pharmaceutical Investment Co., Ltd. completed the acquisition of 5.35% stake in ChemPartner PharmaTech Co.,Ltd. (SZSE:300149) from Yunnan Baben Health Industry Co., Ltd. on May 20, 2025. Reported Earnings • Apr 29
Full year 2024 earnings released: CN¥0.45 loss per share (vs CN¥1.82 loss in FY 2023) Full year 2024 results: CN¥0.45 loss per share (improved from CN¥1.82 loss in FY 2023). Revenue: CN¥970.2m (down 15% from FY 2023). Net loss: CN¥226.5m (loss narrowed 75% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Annuncio • Apr 29
ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 29, 2025 ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 29, 2025, at 14:00 China Standard Time. Annuncio • Mar 31
ChemPartner PharmaTech Co.,Ltd. to Report Q1, 2025 Results on Apr 29, 2025 ChemPartner PharmaTech Co.,Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025 Annuncio • Dec 31
ChemPartner PharmaTech Co.,Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025 ChemPartner PharmaTech Co.,Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025 Annuncio • Nov 16
ChemPartner PharmaTech Co.,Ltd. Approves the Election of Directors ChemPartner PharmaTech Co.,Ltd. held its 2nd Extraordinary General Meeting of 2024 on 14 November 2024, during which the following proposal(s) was/were approved the election of Chen Wanglong as non-independent director and Zhang Xuemei as independent director. Annuncio • Sep 30
ChemPartner PharmaTech Co.,Ltd. to Report Q3, 2024 Results on Oct 30, 2024 ChemPartner PharmaTech Co.,Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024 Reported Earnings • Aug 30
Second quarter 2024 earnings released: CN¥0.076 loss per share (vs CN¥0.011 profit in 2Q 2023) Second quarter 2024 results: CN¥0.076 loss per share (down from CN¥0.011 profit in 2Q 2023). Revenue: CN¥230.6m (down 20% from 2Q 2023). Net loss: CN¥37.4m (down CN¥44.2m from profit in 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 39 percentage points per year, which is a significant difference in performance. Annuncio • Jun 29
ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2024 Results on Aug 30, 2024 ChemPartner PharmaTech Co.,Ltd. announced that they will report first half, 2024 results on Aug 30, 2024 Annuncio • Apr 28
Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 31, 2024 Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 31, 2024, at 14:00 China Standard Time. Location: Building A, No. 2829, Jinke Road, Zhangjiang Hi-tech Park, Pudong New Area, Shanghai China Agenda: To consider 2023 work report of the board of directors; to consider 2023 annual accounts report; to consider 2023 annual report and its summary; to consider 2023 profit distribution plan; to consider Application for comprehensive credit line to banks and other financial institutions and provision of guarantee; to consider Shareholder return plan for the next three years from 2024 to 2026; to consider Authorization to the board to handle matters regarding the share offering to specific parties via a simplified procedure; to consider Change of the Company's business scope and amendments to the Company's articles of association; to consider 2023 work report of the supervisory committee; and to consider other business matters. Reported Earnings • Apr 27
First quarter 2024 earnings released: CN¥0.051 loss per share (vs CN¥0.057 loss in 1Q 2023) First quarter 2024 results: CN¥0.051 loss per share (improved from CN¥0.057 loss in 1Q 2023). Revenue: CN¥234.6m (down 13% from 1Q 2023). Net loss: CN¥25.5m (loss narrowed 11% from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 35 percentage points per year, which is a significant difference in performance. New Risk • Apr 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 21% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (10% average weekly change). Annuncio • Mar 30
Chempartner Pharmatech Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024 Chempartner Pharmatech Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024 Annuncio • Dec 30
Chempartner Pharmatech Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024 Chempartner Pharmatech Co., Ltd. announced that they will report fiscal year 2023 results on Apr 26, 2024 Reported Earnings • Oct 25
Third quarter 2023 earnings released: CN¥0.048 loss per share (vs CN¥0.13 profit in 3Q 2022) Third quarter 2023 results: CN¥0.048 loss per share (down from CN¥0.13 profit in 3Q 2022). Revenue: CN¥288.7m (down 16% from 3Q 2022). Net loss: CN¥19.4m (down 129% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 29
Second quarter 2023 earnings released: EPS: CN¥0.011 (vs CN¥1.90 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.011 (down from CN¥1.90 in 2Q 2022). Revenue: CN¥288.8m (down 3.9% from 2Q 2022). Net income: CN¥6.79m (down 99% from 2Q 2022). Profit margin: 2.4% (down from 315% in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Aug 23
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥7.25, the stock trades at a trailing P/E ratio of 10.6x. Average trailing P/E is 36x in the Biotechs industry in China. Total loss to shareholders of 65% over the past three years. New Risk • Aug 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.4% average weekly change). Large one-off items impacting financial results. Valuation Update With 7 Day Price Move • Aug 03
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥9.47, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 40x in the Biotechs industry in China. Total loss to shareholders of 58% over the past three years. Reported Earnings • Apr 28
First quarter 2023 earnings released: CN¥0.057 loss per share (vs CN¥0.019 profit in 1Q 2022) First quarter 2023 results: CN¥0.057 loss per share (down from CN¥0.019 profit in 1Q 2022). Revenue: CN¥268.7m (down 31% from 1Q 2022). Net loss: CN¥28.6m (down 402% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Apr 27
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to CN¥8.47, the stock trades at a trailing P/E ratio of 7x. Average trailing P/E is 39x in the Biotechs industry in China. Total loss to shareholders of 23% over the past three years. Board Change • Nov 16
Less than half of directors are independent There are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. 2 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Supervisor Jiahui Qi is the most experienced director on the board, commencing their role in 2018. Independent Director Ji Guo Zhang was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Valuation Update With 7 Day Price Move • Nov 11
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥12.23, the stock trades at a trailing P/E ratio of 10x. Average trailing P/E is 39x in the Biotechs industry in China. Total loss to shareholders of 13% over the past three years. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.021 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.13 (up from CN¥0.021 in 3Q 2021). Revenue: CN¥345.3m (down 17% from 3Q 2021). Net income: CN¥66.8m (up CN¥57.1m from 3Q 2021). Profit margin: 19% (up from 2.3% in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Reported Earnings • Sep 01
Second quarter 2022 earnings released: EPS: CN¥1.90 (vs CN¥0.007 in 2Q 2021) Second quarter 2022 results: EPS: CN¥1.90 (up from CN¥0.007 in 2Q 2021). Revenue: CN¥300.6m (down 34% from 2Q 2021). Net income: CN¥947.1m (up CN¥943.6m from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings. Annuncio • Jun 11
Tate & Lyle Investments Limited completed the acquisition of Quantum Hi-Tech (Guangdong) Biological Co., Ltd. from Chempartner Pharmatech Co., Ltd. (SZSE:300149). Tate & Lyle Investments Limited agreed to acquire Quantum Hi-Tech (Guangdong) Biological Co., Ltd. from Chempartner Pharmatech Co., Ltd. (SZSE:300149) for CNY 1500 million on March 30, 2022. Chempartner Pharmatech's board of directors approved the transaction. As November 30, 2022, Quantum Hi-Tech (Guangdong) Biological reported the Total assets of CNY 268,686,400 and Net assets of CNY 172,838,300. The management team of Quantum will join Tate & Lyle at completion. The transaction is subject to approval by the shareholders of ChemPartner. The acquisition is expected to be accretive to revenue growth and EBITDA margin for Tate & Lyle in the first year of ownership. Andrew Boyd and Chuan Sun of Morrison & Foerster (UK) LLP acted as legal advisor to Tate and Lyle.
Tate & Lyle Investments Limited completed the acquisition of Quantum Hi-Tech (Guangdong) Biological Co., Ltd. from Chempartner Pharmatech Co., Ltd. (SZSE:300149) on June 9, 2022. Annuncio • May 10
Chempartner Pharmatech Co., Ltd. announced that it expects to receive CNY 300 million in funding Chempartner Pharmatech Co., Ltd. announced a private placement of A shares for gross proceeds of not more than CNY 300,000,000 on May 8, 2022. The issue price shall not be lower than 80% of the average stock trading price of the 20 trading days prior to the pricing benchmark date. The transaction will include participation from not more than 35 investors. The shares issued will be subject to restriction period of 6 months from closing. The transaction has been approved at the 18th meeting of 5th session of board of directors, subject to 2021 annual general meeting. Annuncio • May 07
Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 23, 2022 Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 23, 2022, at 14:00 China Standard Time. Agenda: To consider 2021 work report of the board of directors; to consider 2021 annual accounts; to consider 2021 annual report and its summary; to consider 2021 profit distribution plan; to consider Provision for goodwill impairment; to consider 2022 estimated continuing connected transactions; to consider an application for comprehensive credit line to banks and other financial institutions; to consider the change of the Company's domicile and amendments to the Company's articles of association; and to consider 2021 work report of the supervisory committee. Reported Earnings • May 02
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: EPS: CN¥0.019 (up from CN¥0.003 in 1Q 2021). Revenue: CN¥386.3m (flat on 1Q 2021). Net income: CN¥9.47m (up 480% from 1Q 2021). Profit margin: 2.5% (up from 0.4% in 1Q 2021). Revenue missed analyst estimates by 5.3%. Earnings per share (EPS) also missed analyst estimates by 18%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance. Annuncio • May 02
Chempartner Pharmatech Co., Ltd. to Report Fiscal Year 2021 Results on Apr 30, 2022 Chempartner Pharmatech Co., Ltd. announced that they will report fiscal year 2021 results on Apr 30, 2022 Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Member of the Supervisory Board Hai Zhang was the last director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Jan 24
Investor sentiment deteriorated over the past week After last week's 21% share price decline to CN¥13.46, the stock trades at a trailing P/E ratio of 77.9x. Average trailing P/E is 46x in the Biotechs industry in China. Total loss to shareholders of 12% over the past three years. Reported Earnings • Nov 01
Third quarter 2021 earnings released: EPS CN¥0.021 (vs CN¥0.085 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥416.1m (up 4.2% from 3Q 2020). Net income: CN¥9.70m (down 77% from 3Q 2020). Profit margin: 2.3% (down from 11% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 30
Second quarter 2021 earnings released: EPS CN¥0.007 (vs CN¥0.11 in 2Q 2020) The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥455.7m (up 16% from 2Q 2020). Net income: CN¥3.51m (down 94% from 2Q 2020). Profit margin: 0.8% (down from 14% in 2Q 2020). Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 5% per year. Valuation Update With 7 Day Price Move • Jun 29
Investor sentiment improved over the past week After last week's 20% share price gain to CN¥20.55, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 44x in the Biotechs industry in China. Total returns to shareholders of 25% over the past three years. Annuncio • May 27
Chempartner Pharmatech Co., Ltd. Announces Final Cash Dividend for 2020, Payable on 1 June 2021 Chempartner Pharmatech Co., Ltd. announced final cash dividend CNY0.70203600 per ten shares (tax included) for 2020, payable on 1 June 2021. The record date is 31 May 2021 and the ex-date is 1 June 2021. Annuncio • May 22
Chempartner Pharmatech Co., Ltd. Approves Cash Dividend for the Year 2020 Chempartner Pharmatech Co., Ltd. at its annual general meeting held on May 20, 2021, approved cash dividend per ten shares (tax included) of CNY 0.70000000 for the year 2020. Valuation Update With 7 Day Price Move • May 14
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥16.39, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 45x in the Biotechs industry in China. Total loss to shareholders of 26% over the past three years. Annuncio • Apr 29
Chempartner Pharmatech Co., Ltd. Announces the Profit Distribution Proposal for 2020 Chempartner Pharmatech Co., Ltd. announced the profit distribution proposal for 2020. The company announced Cash dividend/10 shares (tax included) of CNY 0.70000000. Reported Earnings • Apr 29
First quarter 2021 earnings released: EPS CN¥0.003 (vs CN¥0.028 loss in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥389.7m (up 40% from 1Q 2020). Net income: CN¥1.63m (up CN¥15.8m from 1Q 2020). Profit margin: 0.4% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Mar 15
New 90-day low: CN¥12.64 The company is down 29% from a price of CN¥17.76 on 15 December 2020. Underperformed the Chinese market, which is flat over the last 90 days. Lagged the Biotechs industry, which is down 2.0% over the same period. Is New 90 Day High Low • Jan 28
New 90-day low: CN¥12.66 The company is down 36% from its price of CN¥19.93 on 30 October 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.53 per share. Valuation Update With 7 Day Price Move • Dec 24
Investor sentiment deteriorated over the past week After last week's 19% share price decline to CN¥14.46, the stock is trading at a trailing P/E ratio of 51.2x, down from the previous P/E ratio of 62.9x. This compares to an average P/E of 63x in the Biotechs industry in China. Total returns to shareholders over the past year are 8.9%. Is New 90 Day High Low • Dec 24
New 90-day low: CN¥14.46 The company is down 31% from its price of CN¥20.99 on 25 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.55 per share. Is New 90 Day High Low • Nov 11
New 90-day low: CN¥18.29 The company is down 4.0% from its price of CN¥19.06 on 13 August 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥13.16 per share. Reported Earnings • Oct 30
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥141.1m, up 8.5% from the prior year. Total revenue was CN¥1.44b over the last 12 months, up 8.5% from the prior year. Annuncio • Aug 13
Quantum Hi-Tech (China) Biological Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020 Quantum Hi-Tech (China) Biological Co., Ltd. announced that they will report first half, 2020 results on Aug 28, 2020 
